CD274 and lip and oral cavity carcinoma: The NIDCD group further demonstrated synergy of combinatorial PD-L1 t-haNK, PD-1 blockade, and IL-15 superagonist in the MOC1 syngeneic mouse oral cancer model laying the groundwork for a recently activated phase II trial (n = 55) of this triplet combination in 2nd line recurrent/metastatic HNSCC (NCT04847466).